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•Wystąpienia plakatowe
More detailed analysis of impravements in symptoms has been carried out according to own scoring system for dyspnoea,
cough and haemoptysis. Mean duration of palliative response was 55 days (1-405). Mean survival time was 114 days (2-406).
Conclusion: E-HOR-BT is an effective method of palliation of symptoms related to bronchial obturation in course of lung
cancer. The most frequent serious treatment complication of E-HOR-BTwas massive haemoptysis.
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Purpose: To present data fram Linz, Austria, on survival and local controi of a prospective treatment method and
to demonstrate the safe use of combined external beam and interstitial Iridium-192 HDR irradiation. This method has been
transferred to Gynecological Clinic in Poznan, Poland, where the first implantation was performed in January 2004.
Patients & Methods: a) Linz: Since 1984 HOR Ir-192 brachytherapy has been used to deliver an interstitial boost
to the primary site in conservative breast cancer treatment. Until December 1995, 650 patients have been treated (li : 434, T2:
216, NO: 467, Ni: 183). Treatment method (after tumourectomy or quadrantectomy) included external beam irradiation
of 45 to 50 Gy to the breast folIowed by an interstitial1 OGy boost. Mean follow up of survivors: 105 months (range 36 to 189).
b) Poznan: Ina 54 years old patient with breast cancer carcinoma ductale infiltrans G.2 pT2 tumourectomy was performed.
In the same surgical session hollow needles where implanted into the tumour bed. Using an Iridium-192 source interstitial
radiotherapy was delivered with a dose of 10 Gy as boost to the primary site.
Results: 5-years actuarial data for T1-2 tumours: Overall survival: 89.2%, local controi: 96.9%, disease free survival: 86.4%,
and disease specific survival: 92.8%. There were no severe complications, the cosmetic results are satisfactory (91% good
to excellent after 5 years).
Conclusion: The use of a HDR source in boosting the primary tumour site with a dose of 1OGy in 1 Iraction after external beam
radiotherapy is a safe procedure; the impact on cosmetic results is minimaI. Our 5-year local relapse rate of 3.1 % and survival
data are satisfactory and better compared to most of the results reported in literature. Therefore we will continue with
the described prospective approach in Linz. The first implantation in Poznan was the kick off for further brachytherapy treat-
ments in breast cancer patients. High dose rate implantantions in the treatment of breast cancer will continue at the Gyneco-
logical Clinic in Poznan, either as a boost or as the sole treatment of mammary glant carcinoma.
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Cel pracy: Analizie poddano wpływ wydłużeniaprzerwy między impulsami brachyterapii POR na wartości dawek promie-
niowania w wybranych punktach narządachkrytycznych.
Materiał i metody: Materiał kliniczny wybrany do badań obejmuje 57 kolejnych chorych leczonych metodą brachyterapii
POR. W grupie chorych było 27 mężczyzn (47.4%) i 30 kobiet (52.6%). Średni wiek chorych wynosił 53 lata i mieścił się
w zakresie 22-85 lat (mediana 53.0). Byli to wszyscy chorzy leczeni metodą brachyterapii POR w okresie od maja 1999 raku
do grudnia 2002 roku w Wielkopolskim Centrum Onkologii (WCO). Obliczenia dawek dla brachyterapii POR wykonano
u 15 chorych na nowotwór głowy i szyi, 23 chorych na nowotwór OUN, 8 chorych na raka gruczołu piersiowego, 3 chorych
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